sur QIAGEN N.V. (ETR:QIA)
QIAGEN Appoints Jonathan M. Pratt as CEO
QIAGEN N.V., based in Venlo, Netherlands, has announced the appointment of Jonathan M. Pratt as its new Chief Executive Officer, effective September 1, 2026. Pratt brings over 25 years of leadership experience in life sciences, laboratory technologies, and healthcare sectors. His previous roles include being the President and CEO of Filtration Group, overseeing its transition to Parker-Hannifin Corporation.
Jonathan Pratt's career spans numerous global businesses, with expertise in analytical instruments, laboratory technologies, and bioprocessing. He is set to enhance QIAGEN's focus on profitable growth, operational efficiency, and strategic capital allocation. Thierry Bernard will assist in a smooth transition until year-end as he steps down from his CEO role.
The company remains committed to its strategic objectives and continues to evaluate opportunities for shareholder value enhancement with the help of independent advisors. QIAGEN stands firm on its third-quarter and full-year 2026 outlook, emphasizing the commitment to its growth pillars.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de QIAGEN N.V.